{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,1]],"date-time":"2026-11-01T23:17:07Z","timestamp":1793575027741,"version":"4.5.0"},"reference-count":23,"publisher":"The Journal of Rheumatology","issue":"5","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["J Rheumatol"],"accepted":{"date-parts":[[2025,11,18]]},"published-print":{"date-parts":[[2026,5]]},"abstract":"<jats:sec>\n                    <jats:title>Objective<\/jats:title>\n                    <jats:p>To evaluate whether hip osteoarthritis (OA) is a risk factor for immune checkpoint inhibitor (ICI)-induced inflammatory arthritis (ICI-IA).<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>Patients treated for thoracic cancer with ICI therapy and with computed tomography (CT) of the abdomen\/pelvis within 1 month of ICI start were included; hip OA was graded from a coronal slice of the CT by a radiologist. Chart review determined the presence of ICI-IA and other immune-related adverse events. Those with Kellgren-Lawrence grade of \u2265 2 in either hip on CT abdomen\/pelvis were classified as having hip OA. Incidence rates of ICI-IA were calculated in patients with and without hip OA. Development of ICI-IA and overall survival were compared by Kaplan-Meier curves and Cox proportional hazards.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>\n                      A total of 309 patients were included; 103 had hip OA on CT scan. Overall, the cumulative incidence of ICI-IA was 54.8\/1000 person-years and did not significantly differ between those with and without hip OA (\n                      <jats:italic>P<\/jats:italic>\n                      = 0.78). In the Cox proportional hazards model, hip OA was not associated with ICI-IA development (hazard ratio [HR] 1.24,\n                      <jats:italic>P<\/jats:italic>\n                      = 0.55), but higher BMI was associated with a significantly lower hazard for ICI-IA (HR 0.93,\n                      <jats:italic>P<\/jats:italic>\n                      = 0.049). Survival did not differ by hip OA status but was improved in patients with ICI-IA (HR 0.59,\n                      <jats:italic>P<\/jats:italic>\n                      = 0.02) and higher BMI (HR 0.97,\n                      <jats:italic>P<\/jats:italic>\n                      = 0.03), and was worsened in higher cancer stage (HR 1.60,\n                      <jats:italic>P<\/jats:italic>\n                      &lt; 0.01) in the multivariable analysis.\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusion<\/jats:title>\n                    <jats:p>CT-derived hip OA was not significantly associated with development of ICI-IA in this cohort of patients with lung cancer. ICI-IA was associated with decreased mortality.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.3899\/jrheum.2025-0808","type":"journal-article","created":{"date-parts":[[2026,1,15]],"date-time":"2026-01-15T13:25:15Z","timestamp":1768483515000},"page":"562-568","source":"Crossref","is-referenced-by-count":5,"title":["Evaluating Hip Osteoarthritis as a Risk Factor for Immune Checkpoint Inhibitor\u2013Induced Inflammatory Arthritis"],"prefix":"10.3899","volume":"53","author":[{"given":"Rebecca","family":"Fitzpatrick","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shadpour","family":"Demehri","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Joseph","family":"Murray","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Julie R.","family":"Brahmer","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Elena","family":"Ghotbi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Durrant","family":"Barasa","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"suffix":"III","given":"Clifton O.","family":"Bingham","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ami A.","family":"Shah","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Laura C.","family":"Cappelli","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"2262","published-online":{"date-parts":[[2026,1,15]]},"reference":[{"key":"2026050105301092000_53.5.562.1","doi-asserted-by":"publisher","DOI":"10.1038\/nrc3239"},{"key":"2026050105301092000_53.5.562.2","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMra1703481"},{"key":"2026050105301092000_53.5.562.3","first-page":"4019","article-title":"Immune checkpoint inhibitors: immune-related adverse events, healthcare utilization, and costs among commercial and Medicare Advantage patients","volume":"30","author":"Gunturu","year":"2022","journal-title":"Support Care Cancer"},{"key":"2026050105301092000_53.5.562.4","doi-asserted-by":"crossref","first-page":"32","DOI":"10.1186\/s41927-020-00133-8","article-title":"Immune checkpoint inhibitor-induced inflammatory arthritis: a qualitative study identifying unmet patient needs and care gaps","volume":"4","author":"Cappelli","year":"2020","journal-title":"BMC Rheumatol"},{"key":"2026050105301092000_53.5.562.5","doi-asserted-by":"crossref","first-page":"303","DOI":"10.1002\/acr2.1026","article-title":"Sonographic findings in inflammatory arthritis secondary to immune checkpoint inhibition: a case series","volume":"1","author":"Albayda","year":"2019","journal-title":"ACR Open Rheumatol"},{"key":"2026050105301092000_53.5.562.6","doi-asserted-by":"publisher","DOI":"10.1136\/annrheumdis-2019-216109"},{"key":"2026050105301092000_53.5.562.7","doi-asserted-by":"crossref","first-page":"175","DOI":"10.1007\/s00262-017-2069-9","article-title":"Characterization of arthralgia induced by PD-1 antibody treatment in patients with metastasized cutaneous malignancies","volume":"67","author":"Buder-Bakhaya","year":"2017","journal-title":"Cancer Immunol Immunother"},{"key":"2026050105301092000_53.5.562.8","doi-asserted-by":"publisher","DOI":"10.1038\/nrrheum.2010.196"},{"key":"2026050105301092000_53.5.562.9","doi-asserted-by":"crossref","first-page":"33","DOI":"10.1038\/nrrheum.2010.196","article-title":"Role of proinflammatory cytokines in the pathophysiology of osteoarthritis","volume":"7","author":"Kapoor","year":"2011","journal-title":"Nat Rev Rheumatol"},{"key":"2026050105301092000_53.5.562.10","doi-asserted-by":"crossref","first-page":"5027","DOI":"10.3390\/jcm10215027","article-title":"Synovial fluid cytokines, chemokines and MMP levels in osteoarthritis patients with knee pain display a profile similar to many rheumatoid arthritis patients","volume":"10","author":"Meehan","year":"2021","journal-title":"J Clin Med"},{"key":"2026050105301092000_53.5.562.11","doi-asserted-by":"crossref","first-page":"198","DOI":"10.1097\/CJI.0000000000000366","article-title":"Immunotherapy utilization among patients with metastatic NSCLC: impact of comorbidities","volume":"44","author":"Zhang","year":"2021","journal-title":"J Immunother"},{"key":"2026050105301092000_53.5.562.12","doi-asserted-by":"publisher","DOI":"10.1186\/s40425-018-0417-8"},{"key":"2026050105301092000_53.5.562.13","doi-asserted-by":"crossref","first-page":"104","DOI":"10.1186\/s40425-018-0417-8","article-title":"Immune-related adverse events with immune checkpoint inhibitors affecting the skeleton: a seminal case series","volume":"6","author":"Moseley","year":"2018","journal-title":"J Immunother Cancer"},{"key":"2026050105301092000_53.5.562.14","doi-asserted-by":"publisher","DOI":"10.1136\/jitc-2021-003260"},{"key":"2026050105301092000_53.5.562.15","doi-asserted-by":"publisher","DOI":"10.1136\/jitc-2024-010758"},{"key":"2026050105301092000_53.5.562.16","doi-asserted-by":"crossref","first-page":"e010758","DOI":"10.1136\/jitc-2024-010758","article-title":"Osteoarthritis increases the risk of inflammatory arthritis due to immune checkpoint inhibitors associated with tissue-resident memory T cells","volume":"13","author":"Paiola","year":"2025","journal-title":"J Immunother Cancer"},{"key":"2026050105301092000_53.5.562.17","doi-asserted-by":"crossref","first-page":"171","DOI":"10.1038\/s41584-021-00747-3","article-title":"Erosive hand osteoarthritis: latest findings and outlook","volume":"18","author":"Favero","year":"2022","journal-title":"Nat Rev Rheumatol"},{"key":"2026050105301092000_53.5.562.18","doi-asserted-by":"publisher","DOI":"10.1093\/rheumatology\/keac519"},{"key":"2026050105301092000_53.5.562.19","doi-asserted-by":"crossref","first-page":"1451","DOI":"10.1093\/rheumatology\/keac519","article-title":"Immune checkpoint inhibitor-induced arthralgia is tightly associated with improved overall survival in cancer patients","volume":"62","author":"Maeda","year":"2023","journal-title":"Rheumatology"},{"key":"2026050105301092000_53.5.562.20","doi-asserted-by":"publisher","DOI":"10.1016\/j.joca.2014.03.008"},{"key":"2026050105301092000_53.5.562.21","doi-asserted-by":"publisher","DOI":"10.1186\/1471-2474-9-132"},{"key":"2026050105301092000_53.5.562.22","doi-asserted-by":"crossref","first-page":"132","DOI":"10.1186\/1471-2474-9-132","article-title":"Obesity and osteoarthritis in knee, hip and\/or hand: an epidemiological study in the general population with 10 years follow-up","volume":"9","author":"Grotle","year":"2008","journal-title":"BMC Musculoskelet Disord"},{"key":"2026050105301092000_53.5.562.23","doi-asserted-by":"crossref","first-page":"527","DOI":"10.1002\/art.41949","article-title":"Predictors of rheumatic immune-related adverse events and de novo inflammatory arthritis after immune checkpoint inhibitor treatment for cancer","volume":"74","author":"Cunningham-Bussel","year":"2022","journal-title":"Arthritis Rheumatol"}],"container-title":["The Journal of Rheumatology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/syndication.highwire.org\/content\/doi\/10.3899\/jrheum.2025-0808","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,5,1]],"date-time":"2026-05-01T12:30:40Z","timestamp":1777638640000},"score":1,"resource":{"primary":{"URL":"http:\/\/www.jrheum.org\/lookup\/doi\/10.3899\/jrheum.2025-0808"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,1,15]]},"references-count":23,"journal-issue":{"issue":"5","published-online":{"date-parts":[[2026,5,1]]},"published-print":{"date-parts":[[2026,5]]}},"alternative-id":["10.3899\/jrheum.2025-0808"],"URL":"https:\/\/doi.org\/10.3899\/jrheum.2025-0808","relation":{},"ISSN":["0315-162X","1499-2752"],"issn-type":[{"value":"0315-162X","type":"print"},{"value":"1499-2752","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,1,15]]}}}